文献速递肾癌与肾肿瘤

肾癌诊断的新型液体生物标志物与创新影像:系统综述

Novel Liquid Biomarkers and Innovative Imaging for Kidney Cancer Diagnosis: What Can Be Implemented in Our Practice Today? A Systematic Review of the Literature.
PubMed 文献 · Eur Urol Oncol · 2021-01-03

该系统综述评估了液体生物标志物与创新影像在肾细胞癌(RCC)诊断中的价值。纳入15项研究(6项生物标志物、9项影像)及8项临床试验,未发现任何标志物或影像模态经验证或具有明确临床价值。尿液游离/外泌体miRNA组合、尿液miR-15a及代谢组学面板、机器/深度学习与影像组学显示前景,但多数研究受回顾性设计、样本量小及缺乏外部验证限制。

要点

  • 目前无液体生物标志物或创新影像经验证可用于RCC临床诊断。
  • 尿液miRNA组合与代谢组学面板、影像组学与深度学习显示初步前景。
  • 现有研究多为回顾性、样本量小且缺乏外部验证,尚不能临床整合。

核心结论

  • 液体生物标志物或影像模态尚未准备好在临床中整合,需要进一步设计良好的研究验证初步发现并探索临床决策效用。

研究设计与样本

  • 系统综述遵循欧洲泌尿外科学会指南与PRISMA声明(PROSPERO ID: CRD42020190773),检索MEDLINE、Cochrane Central Register of Controlled Trials、Web of Science和ClinicalTrials.gov数据库。
  • 共纳入15项研究(6项关于生物标志物,9项关于影像)和8项临床试验,使用QUADAS 2工具进行偏倚风险评估。

主要发现

  • 没有任何生物标志物或影像模态被验证或显示出对RCC的明确临床价值。
  • 尿液游离和exosomal miRNA的特定组合、尿液miR-15a以及通过代谢组学评估的特定尿液代谢物面板似乎有前景。
  • 应用于横断面图像的机器/深度学习算法和影像组学可能具有改善RCC诊断的潜力。
  • 大多数研究受限于回顾性设计、样本量小和缺乏外部验证。

临床怎么用

  • 目前液体生物标志物或影像模态尚不能整合入临床,不应在临床决策中常规使用。
  • 对于疑似RCC的患者,组织病理学分析仍是诊断金标准。

局限性

  • 大多数研究为回顾性设计,样本量小,且缺乏外部验证。
  • 纳入研究数量有限(15项研究及8项临床试验),可能影响结论的稳健性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The epidemiological signature of renal cell carcinoma (RCC) during the past decades is explained by overdetection and overtreatment of indolent cancers; furthermore, a non-negligible proportion of patients undergoing surgery for suspected RCC harbour benign renal tumours. As the gold standard for RCC diagnosis remains histopathological analysis of surgical or biopsy specimens, implementation of noninvasive diagnostic strategies to discriminate between benign and malignant renal masses is an urgent unmet need. OBJECTIVE: To systematically review novel liquid biomarkers and imaging modalities for RCC diagnosis. EVIDENCE ACQUISITION: A systematic review of the recent English-language literature was conducted according to the European Association of Urology guidelines and the PRISMA statement recommendations (PROSPERO ID: CRD42020190773) using the MEDLINE, Cochrane Central Register of Controlled Trials, Web of Science, and ClinicalTrials.gov databases. Risk-of-bias assessment was performed according to the QUADAS 2 tool. EVIDENCE SYNTHESIS: Overall, 15 studies (six on biomarkers and nine on imaging) and eight clinical trials were included. None of the biomarkers or imaging modalities has been validated or shown to have a distinct clinical value for RCC. Specific combinations of urinary cell-free and exosomal miRNAs, urinary miR-15a, and specific panels of urinary metabolites assessed by metabolomics appear promising. In addition, machine/deep learning algorithms and radiomics applied to cross-sectional images may have potential to improve RCC diagnosis. Most studies are limited by the retrospective design, size, and lack of external validation. CONCLUSIONS: Liquid biomarkers or imaging modalities are not ready for integration in the clinic and further well-designed studies must validate preliminary findings and explore utility in clinical decision-making. PATIENT SUMMARY: We provide a comprehensive overview of the currently available biomarkers (measured in blood or urine) and novel imaging tests (other than conventional imaging) to discriminate kidney cancer from benign renal masses in a noninvasive fashion. None of the biomarkers or imaging modalities studied was validated or added clinical value; therefore, none of them can be implemented in the clinic. However, these approaches appear to be promising for improving the diagnosis of kidney cancer in the future.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Campi R, Stewart GD, Staehler M, et al. Novel Liquid Biomarkers and Innovative Imaging for Kidney Cancer Diagnosis: What Can Be Implemented in Our Practice Today? A Systematic Review of the Literature. Eur Urol Oncol. 2021. PMID: 33408053. doi:10.1016/j.euo.2020.12.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。